RT Journal Article
ID 171ce94b0b6a30d5
A1 Qadir, Muhammad Imran
A1 Zafar, Maria
T1 TSG101: Tumor Susceptibility Gene 101 (tsg101) Product−Role in Therapy Against HIV/AIDS
JF Critical Reviews™ in Eukaryotic Gene Expression
JO CRE
YR 2017
FD 2017-09-29
VO 27
IS 3
SP 237
OP 246
K1 tumor susceptibility gene 101 (tsg101)
K1 HIV
K1 monoclonal antibody
K1 CB8-2
K1 HIV/AIDS therapy
K1 UEV,
TSG101
AB HIV infection presents a major community health hazard, partially because the HIV virus is capable
of evading antiretroviral therapies. Most anti-HIV drugs were intended to target virus-encoded mechanisms; however,
some host-encoded molecules comparatively execute a vital role in the life cycle of virus. Thus, these might
be considered as target sites for antiviral agents. TSG101 is important among these antiviral therapies because, as
a cytoplasmic molecule, it facilitates viral budding and release. In this review, HIV-infected cells have TSG101 on
their surface and thus can be used in antibody-based therapies. The development of a monoclonal antibody CB8-2
lessens the assembly of viruses from infected cells. This mechanism represents the potential use of TSG101-directed
antibodies to fight against AIDS.
PB Begell House
LK https://www.dl.begellhouse.com/journals/6dbf508d3b17c437,3e1db9ff199ae23c,171ce94b0b6a30d5.html